<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912211442
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AZI-ONCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Azi-Once&trade; is one of a group of antibiotics called macrolides. It is used to treat<br />infections caused by certain bacteria and other micro-organisms which include:<br />&bull; chest, throat or nasal infections (such as bronchitis, pneumonia, tonsillitis, sore<br />throat (pharyngitis) and sinusitis).<br />&bull; ear infections.<br />&bull; skin and soft tissue infections (such as an abscess or boil).<br />&bull; sexually-transmitted diseases caused by an organism called chlamydia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Azi-Once&trade; if you/your child:<br />&bull; are allergic to Azi-Once&trade; or any other macrolide antibiotic such as erythromycin or<br />clarithromycin or any of the ingredients listed in section 6. An allergic reaction may<br />cause skin rash or wheezing.<br />&bull; you are taking any ergot derivatives such as ergotamine (used to treat migraine) as<br />these medicines should not be taken together with Azi-Once&trade;.<br />Take special care with Azi-Once&trade;<br />Your doctor needs to know before you take Azi-Once&trade; if you/your child have or<br />have had any of the following:<br />&bull; kidney problems. &bull; heart conditions. &bull; diabetes .<br />&bull; liver problems: your doctor may need to monitor your liver function or stop the<br />treatment.<br />&bull; and if you are taking any ergot derivatives such as ergotamine (used to treat<br />migraine) as these medicines should not be taken together with Azi-Once&trade;.<br />Tell your doctor immediately if you feel your heart beating in your chest or have an<br />abnormal heartbeat, or get dizzy or faint or suffer from any muscle weakness when<br />taking Azi-Once&trade;.<br />Prolonged cardiac repolarization and QT interval, imparting a risk of developing<br />cardiac arrhythmia and torsades de pointes, have been seen in treatment with<br />macrolides, including azithromycin. Cases of torsades de pointes have been<br />spontaneously reported during postmarketing surveillance in patients receiving<br />azithromycin.<br />Providers should consider the risk of QT prolongation which can be fatal when<br />weighing the risks and benefits of azithromycin for at-risk groups including:<br />&bull; patients with known prolongation of the QT interval, a history of torsades de<br />pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart<br />failure.<br />&bull; patients on drugs known to prolong the QT interval.<br />&bull; patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or<br />hypomagnesemia, clinically significant bradycardia, and in patients receiving Class<br />IA (quinidine, procainamide) or Class III (dofetilide, aminodarone, sotalol)<br />antiarrhythmic agents.<br />Elderly patients may be more susceptible to drug-associated effects on the QT<br />interval.<br />If you develop diarrhoea or loose stools during or after treatment, tell your doctor at<br />once. Do not take any medicine to treat your diarrhoea without first checking with<br />your doctor. If your diarrhoea continues, please inform your doctor.<br />Talk to your doctor before taking azithromycin if you:<br />&bull; have been diagnosed with a neurological disease, which is a disease of the brain or<br />nervous system.<br />&bull; have mental, emotional or behavioural problems.<br />&bull; have a condition known as myasthenia gravis, with fatigue and exhaustion of the<br />muscles: azithromycin may worsen or cause symptoms of myasthenia.<br />&bull; Azithromycin is not recommended for patients under 6 months of age.<br />In patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide,<br />aminodarone, sotalol) antiarrhythmic agents (used to treat abnormal heart<br />rhythms), cisapride (used to treat stomach problems) or terfenadine (an antihistamine<br />that is used to treat allergies): azithromycin is not recommended.<br />Taking other medicines<br />Tell your doctor before taking or giving Azi-Once&trade; if you/your child are taking any<br />of the medicines listed below:<br />&bull; ergot or ergotamine, see &lsquo;Take special care&rsquo; section.<br />&bull; warfarin or any similar medicine to prevent blood clots.<br />&bull; ciclosporin (used to suppress the immune system to prevent and treat rejection of a<br />transplanted organ or bone marrow).<br />&bull; antacids (for indigestion).<br />&bull; digoxin (used to treat heart failure).<br />&bull; Zidovudine, nelfinavir (used in the treatment of HIV).<br />&bull; Statins (such as atorvastatin, used to lower lipids in blood).<br />&bull; Rifabutin (used in the treatment bacterial infections including tuberculosis).<br />&bull; Cisapride (used to treat stomach problems).<br />&bull; Astemizole, terfenadine (antihistamines used to treat allergic reactions).<br />&bull; Alfentanil (a painkiller).<br />&bull; Fluconazole (for fungal infections).<br />&bull; colchicine (used for gout and familial Mediterranean fever).<br />You should always tell your doctor if you/your child are taking or have recently taken<br />any other medicines including those obtained without a prescription.<br />Taking Azi-Once&trade; with food and drink<br />Azi-Once&trade; is not affected by food or drink.<br />Pregnancy and breast-feeding<br />If you are pregnant, trying to become pregnant or are breast-feeding you should not<br />take Azi-Once&trade; without discussing it with your doctor first.<br />Driving and using machines<br />Azi-Once&trade; is not expected to affect your ability to drive or use machines.<br />Important information about some of the ingredients of Azi-Once&trade;<br />This medicine contains sucrose, a type of sugar (3.69g in 5ml).<br />If you have been told by your doctor that you have an intolerance to some sugars<br />contact your doctor before taking Azi-Once&trade;.<br />If you are diabetic, you may need to take this into account in your diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take or give Azi-Once&trade; exactly as your doctor has told you. You should<br />check with your doctor or pharmacist if you are not sure.<br />Azi-Once&trade; suspension is generally used for children 6 months and above. It may<br />also be used in adults and older children who have difficulty swallowing capsules.<br />Children under 45kg<br />The usual dose in children is 10mg for each kg of body weight, given as a single daily<br />dose for 3 days.<br />Adults and children over 45kg<br />The usual dose in adults and in children over 45kg is 500mg taken as a single dose,<br />for 3 days.<br />You should tell your doctor if you/your child have kidney or liver problems as your<br />doctor may need to alter the normal dose.<br />Doctors sometimes prescribe different doses to these. The label on the pack will tell<br />you which dose you/your child should take. If you are still not sure, ask your doctor<br />or pharmacist.<br />Always continue with the course of treatment even if you/your child feel better. If<br />your infection gets worse or you do not start to feel better within a few days or a new<br />infection develops, go back and see your doctor.<br />How to give Azi-Once&trade; Suspension in children less than 3 years of age<br />If your child is under three years of age or weighs up to 15kg in body weight, you<br />should measure the dose as clearly as possible using the 10ml oral dosing syringe<br />provided. The syringe is graduated in 0.25 ml divisions, providing 10mg of<br />azithromycin (the active ingredient) in every graduation.<br />Instructions for the syringe<br />1. Add the water provided in the pack to the powder in the bottle<br />(in the first use only).<br />2. Shake it very well to obtain a homogeneous suspension.<br />3. Use the syringe to draw the required volume after removal of its cover.<br />4. Deliver the dose smoothly by syringe inside your child mouth.<br />5. Wash the syringe, cover it and return it to the pack for the next dose.<br />How to give Azi-Once&trade; Suspension in children between 3 and 14 years of age</p><table cellspacing="1" cellpadding="1" border="1"><tbody><tr><td>Body weight and age</td><td>Dose and duration</td></tr><tr><td>15-25kg body weight (3-7 years)</td><td>5ml (200mg), given as 1 x 5ml spoonful,once daily for 3 days.</td></tr><tr><td>26-35kg body weight (8-11 years):</td><td>7.5ml (300mg), given as 1 x 7.5ml spoonful,once daily for 3 days.</td></tr><tr><td>36-45kg body weight (12-14 years):</td><td>10ml (400mg), given as 1 x 10ml spoonful,once daily for 3 days.</td></tr></tbody></table><p>Warning: if giving this medicine to a child, ensure that while receiving the medicine he/she is supported in an upright position to avoid the risk of choking. If you/your child takes more Azi-Once&trade; than they should If you/your child take too much Azi-Once&trade; they may feel unwell. Tell your doctor or contact your nearest hospital casualty department immediately. Take any remaining medicine with you. If you forget to take or give Azi-Once&trade; If you forget to take Azi-Once&trade; take it as soon as you can. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose. If you stop taking Azi-Once&trade; If you/your child stop taking Azi-Once&trade; too soon, the infection may return. &nbsp;Take Azi-Once&trade; for the full time of treatment, even when you/your child begin to feel better. If you have any further questions about the use of this product, ask your doctor or pharmacist for advice.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines Azi-Once&trade; can cause side effects although not everybody gets them. Tell your doctor immediately if you experience any of the following symptoms after taking this medicine as the symptoms can be severe. &nbsp;&bull; sudden wheeziness, difﬁculty in breathing, swelling of eyelids, face or lips, rash &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;or itching (especially affecting the whole body) &bull; severe or prolonged diarrhoea, which may have blood or mucus in it, during or &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;after treatment with Azi-Once&trade; as this may be a sign of serious bowel inﬂammation &bull; severe skin rash causing redness and ﬂaking &bull; rapid or irregular heartbeat &nbsp;&bull; low blood pressure&bull; Serious skin reactions: - blistering of the skin, mouth, eyes and genitals (Stevens-Johnson Syndrome (SJS)) - blistering of the skin, severe skin reaction (Toxic Epidermal Necrosis (TEN)) - skin rash accompanied by other symptoms such as fever, swollen glands and an increase of eosinophils (a type of white blood cell). A rash appears as small, itchy red bumps (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)) - skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters ﬁlled with white/yellow ﬂuid) (Acute Generalized Exanthematous Pustulosis (AGEP)). Stop taking azithromycin if you develop these skin symptoms and contact your doctor or seek medical attention immediately.The most common side effects that occur when taking Azi-Once&trade; are listed below. These may go away during treatment as your body adjusts to the medicine. Tell your doctor if any of these side effects continue to bother you: Very common side effects (occurring in at least 1 in 10 people taking Azi-OnceTM): &bull; stomach cramps, feeling sick, diarrhoea, wind Common side effects (likely to occur in less than 1 in 10 people) dizziness, headache, numbness or pins and needles, being sick, indigestion, loss of appetite, taste disturbance, visual disturbances, deafness, skin rash and /or itching, joint pain, low numbers of lymphocytes (type of white blood cells), higher number of eosinophils (type of white blood cells), low blood bicarbonate and tiredness or weakness</p><p>Uncommon side effects that occur in less than 1 in 100 people taking Azi-Once&trade; are: yeast infections of the mouth and vagina (thrush), low numbers of leukocytes (type of white blood cells), low number of neutrophils (type of white blood cells), allergic reactions of various severity, blistering of the skin, mouth, eyes and genitals, skin more sensitive to sunlight than normal, feeling nervous, reduced sense of touch or sensation (hypoesthesia), sleepness or sleeplessness (insomnia), poor hearing or ringing in the ears, heart palpitations, chest pain, constipation, stomach pain associated with diarrhoea and fever, inﬂammation of the liver (hepatitis), changes in liver enzymes, general loss of strength, swelling, general discomfort and abnormal laboratory test values (e.g. blood or liver tests). Rare side effects that occur in less than 1 in 1,000 people taking Azi-OnceTM are: agitation, vertigo and changes in liver function Other side effects that have been reported, but it is not known how frequently they occur: ﬁts or fainting, aggression or anxiety, feeling hyperactive, localised muscle weakness, loss of smell or altered sense of smell, loss of taste, tongue discolouration, inﬂammation of the pancreas (pancreatitis), inﬂammation of the kidney or kidney failure, yellowing of the skin or eyes (jaundice) or liver failure (rarely life-threatening), bruising or prolonged bleeding after injury, abnormal electrocardio-gram (ECG) and reduction in red blood cells which can make the skin pale and cause weakness or breathlessness. If any of the side effects get serious, or if you notice any side effects not listed in this leaﬂet, please tell your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep all medicines out of the sight and reach of children.Store dry powder at temperature not exceeding 30 &ordm;C, and after reconstitution store at temperature not exceeding 30 &ordm;C. Discard any unused portion after 5 days of reconstitution.Do not take or give this medicine after the expiry date which is stated on the bottle. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is azithromycin (200mg in 5ml).Other ingredients are Banana ﬂavor, Colloidal silicon dioxide, Fantasy ﬂavor permaseal, Fresh co forte ﬂavor permaseal, Hydroxypropyl cellulose, SucroseTrisodium phosphate monohydrate, Xanthan gum and Puriﬁed water.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Azi-Once™ Suspension: White to off white granular powder with characteristic banana ﬂavor, free from lumps and visible contamination, ﬁlled in 60 mL glass bottles with child resistant cap for preparation of suspension taken by mouth 200mg/5ml.Azi-Once™ Suspension available in three packages containing an oral dosing syringe and : powder to make 15ml (600 mg), powder to make 22.5 ml (900 mg) and powder to make 30 ml (1200 mg).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,&nbsp;Jeddah, Saudi Arabia.</p><p>Tel: +966-12-6081111, Fax: +966-12-6081222.</p><p>Website: www.jamjoompharma.com</p><p>To report any side effect(s):&bull;</p><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />Reporting hotline: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&bull; Other GCC States:&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaﬂet was last approved in 10/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><br />ينتمي أزي- ونس إلى فئة من المضادات الحيوية تسمى الماكروليد. يستخدم لعلاج العدوى التي<br />تسببها بعض أنواع البكتيريا والجسيمات الدقيقة الأخرى وتشمل:<br />&bull; العدوى الصدرية وعدوى الحلق والأنف ( مثل الالتهاب الشعبي والالتهاب الرئوي والتهاب اللوزتين<br />واحتقان الحلق (التهاب البلعوم) والتهاب الجيوب الانفية.<br />&bull; عدوى الأذن.<br />&bull; عدوى الجلد والأنسجة الرخوة ( مثل الخراج والدمامل).<br />&bull; الأمراض المنقولة جنسيا والتي يسببها جسيم يسمى الكلاميديا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم أزي- ونس<br />أو أي مضاد حيوي آخر من نوع الماكروليد مثل إريثرومايسين&nbsp;&nbsp;كان لديك حساسية ضد أزي- ونس<br />أو كلاريثرومايسين أو أي من مكونات الدواء الأخرى المذكورة في الجزء رقم ٦ بهذه النشرة</p><p>. التفاعلالتحسسي من الممكن أن يسبب طفح جلدي أو صفير.<br />&bull; إذا كنت تتناول أي من مشتقات الإرجوت مثل إرجوتامين (يستخدم لعلاج الصداع النصفي) حيث أنه<br />.&trade; يحظر استخدام هذه الادوية بجانب أزي- ونس<br />بحذر &trade; استخدم أزي- ونس<br />يحتاج الطبيب أن يعرف إذا كنت أنت أو طفلك تنطبق عليك أي من الحالات الآتية قبل استخدامك ل&nbsp;أزي- ونس:<br />&bull; كان لديك مشاكل في الكلى. &bull; كان لديك مشاكل في القلب. كنت مصابا بمرض السكري.<br />&bull; كان لديك مشاكل في الكبد: قد يحتاج الطبيب لمراقبة وظائف الكبد لديك أو وقف العلاج.<br />&bull; إذا كنت تتناول أي من مشتقات الإرجوت مثل إرجوتامين (يستخدم لعلاج الصداع النصفي) حيث أنه<br />. يحظر استخدام هذه الادوية بجانب أزي- ونس<br />أخبر طبيبك إذا شعرت بضربات قلبك في الصدر أو إذا شعرت بأي ضربات قلب غير طبيعية أو إذا<br />.شعرت بالدوار أو الإغماء أو إذا كنت تعاني من وهن في العضلات عند استخدامك ل أزي- ونس<br />وقد شوهدت مع العلاج بالماكروليدات بما في ذلك أزيثرومايسين عودة اطالة الاستقطاب للقلب وتسرع<br />القلب متباين قوة النبض، مما يضفي خطرعدم انتظام ضربات القلب. وقد سجلت عفويا خلال المراقبة<br />بعد التسويق حالات تسرع القلب متباين قوة النبض في المرضى الذين يتلقون أزيثروميسين.<br />تسرع القلب متباين قوة النبض التي يمكن أن تكون (QT) ينبغي للمزودين النظر في مخاطر إطالة<br />قاتلة عندما تزن المخاطر والمنافع من أزيثروميسين للفئات المعرضة للخطر بما في ذلك:<br />تسرع القلب متباين قوة النبض، أو تاريخ من (QT) &bull; المرضى الذين يعانون من إطالة فترة<br />الخلقية، بطئ ضربات القلب أو قصور القلب غير (QT) متلازمة إطالة فترة ،torsades de pointes<br />المعوض.<br />(QT) &bull; المرضى على الأدوية المعروفة بإطالة فترة<br />&bull; المرضى الذين يعانون من ظروف حالية لقبل عدم انتظام ضربات القلب مثل حالات نقص بوتاسيوم<br />الدم غير المصححة، نقص مغنيزيوم الدم، بطء القلب الواضح سريريا، والمرضى الذين يتلقون في<br />كينيدين، بروكاينأميد) أو من الدرجة الثالثة (دوفيتليد، امينودارون، سوتالول) ادوية مضادات ) AI فئة<br />ارتفاع معدل ضربات القلب.<br />.(QT) قد يكون المرضى المسنين أكثر عرضة للآثار الادوية المرتبطة بفترة<br />إذا حدث إسهال أو براز ناعم أثناء استخدام الدواء، أخبر طبيبك على الفور. لا تأخذ دواء لعلاج<br />الإسهال قبل مراجعة الطبيب أولاً. إذا استمر الإسهال يجب عليك إخبار طبيبك.<br />تحدث إلى طبيبك قبل تناول أزيثروميسين إذا كنت:<br />&bull; تم تشخيصك بمرض عصبي ، وهو مرض يصيب الدماغ أو الجهاز العصبي.<br />&bull; لديك مشاكل عقلية أو عاطفية أو سلوكية.<br />&bull; لديهم حالة تعرف باسم الوهن العضلي الوبيل ، مع التعب والإرهاق للعضلات: أزيثروميسين قد يزيد<br />أعراض الوهن العضلي سوءا أو يسببها .<br />&bull; لا ينصح باستخدام أزيثروميسين للمرضى دون سن ٦ أشهر من العمر.<br />كينيدين ، ) IA المرضى الذين يستخدمون أدوية لعلاج عدم انتظام ضربات القلب من فئة<br />دوفتيليدي ، أمينوديلون ، السوتالول) التي تستخدم لعلاج الإيقاعات غير ) III بروكاييناميد) أو الفئة<br />الطبيعية في القلب) ، سيسابريد (يستخدم لعلاج مشاكل المعدة) أو تيرفينادين (مضاد للهستامين يستخدم<br />لعلاج الحساسية): لا ينصح بإستخدام أزيثروميسين معهم.<br />استخدم الأدوية الأخرى<br />إذا كنت أنت أو طفلك تتناول أي من الأدوية&nbsp;التالية&nbsp;أخبر طبيبك قبل أن تتناول أو تعطي لطفلك أزي- ونس<br />&nbsp;إرجوت أو إرجوتامين (انظر الجزء: استخدم أزي- ونس<br />&bull; الوارفارين أو أي أدوية مماثلة تمنع تجلط الدم.<br />&bull; سايكلوسبورين ( يستخدم للتخفيض من عمل الجهاز المناعي لمنع رفض الجسم لزرع عضو أو نخاع<br />عظام).<br />&bull; مضادات الحموضة (لحالات عسر الهضم).<br />&bull; ديجوكسين (يستخدم في علاج السكتة القلبية).<br />&bull; زيدوفودين ، نلفينافير (يستخدم في علاج فيروس نقص المناعة البشرية).<br />&bull; استاتين (مثل أتورفاستاتين ، يستخدم لخفض الدهون في الدم).<br />&bull; ريبوفلافين (يستخدم في علاج العدوى البكتيرية بما في ذلك السل).<br />&bull; سيسابريد (يستخدم لعلاج مشاكل في المعدة).<br />&bull; استيميزول، تيرفينادين (مضادات الهيستامين المستخدمة لعلاج تفاعلات الحساسية).<br />&bull; الفنتانيل (مسكن للألم).<br />&bull; فلوكونازول (للالتهابات الفطرية).<br />&bull; الكولشيسين (يستخدم لعلاج النقرس وحمى البحر الأبيض المتوسط).<br />يجب دائما إخبار طبيبك إذا كنت تتناول أو تناولت منذ فترة وجيزة أي دواء آخر بما في ذلك الادوية<br />التي تتناولها بدون وصفة طبية.<br />استخدام أزي- ونس مع الطعام أو الشراب<br />لا يتأثر أزي- ونس بالطعام أو الشراب&nbsp;<br />الحمل والإرضاع</p><p>إذا كنتِ حاملاً أو تخططين للحمل أو كنتِ مرضعة ، لا يجب عليك تناول أزي- ونس&nbsp;قبل مراجعة الطبيب أولاً.<br />قيادة المركبات وتشغيل المعدات<br />&nbsp; ليس من المتوقع أن يؤثر أزي- ونس على قدرتك على قيادة المركبات وتشغيل المعدات.</p><p>&nbsp;معلومات هامة حول بعض مكونات أزي- ونس<br />يحتوى هذا الدواء علي السكروز وهو نوع من انواع السكريات ( ۳٫٦۹ جم في كل ٥ مل). إذا أخبرك&nbsp;الطبيب أن لديك حساسية ضد بعض أنواع السكريات،&nbsp;يرجى استشارته قبل استخدام أزي- ونس إذا كنت مريض بالسكري يجب أن تضع ذلك في الحسبان فيما يخص نظامك الغذائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عليك تناول أزي- ونس أو إعطاؤه لطفلك تماما كما أخبرك الطبيب. إذا لم تكن متأكدا يرجى مراجعة الطبيب أو الصيدلي.<br />يستخدم بشكل عام للأطفال من سن ٦ أشهر فما فوق. قد يستخدم مع البالغين أو &trade; معلق أزي- ونس<br />الأطفال الأكبر سنا في حالة وجود صعوبة في ابتلاع الكبسولات.<br />الأطفال الأقل من ٤٥ كجم<br />الجرعة المعتادة للأطفال هي ۱۰ ملجم/كجم كجرعة يومية واحدة لمدة ۳ أيام.<br />البالغين والاطفال الأكثر من ٤٥ كجم<br />الجرعة المعتادة للبالغين والأطفال الأكثر من ٤٥ كجم هي ٥۰۰ ملجم تؤخذ كجرعة يومية واحدة لمدة<br />۳ أيام.<br />يجب عليك إخبار الطبيب إذا كنت تعاني أنت او طفلك من أي مشاكل في الكبد والكلى حيث أن ذلك قد<br />يؤدي لتعديل الجرعة الاعتيادية. في بعض الأحيان يقوم الأطباء بتحديد جرعات مختلفة عن الجرعات<br />السابقة. الملصق على العبوة سوف يخبرك عن الجرعة التي ينبغى عليك أو على طفلك تناولها. إذا<br />كنت لا تزال غير متأكد استشر طبيبك أو الصيدلي.<br />يجب عليك إكمال عدد الجرعات المطلوبة حتى لو شعرت أو شعر طفلك بالتحسن. إذا زادت العدوى<br />أو إذا لم تشعر بالتحسن خلال أيام قليلة أو إذا ظهرت عدوى جديد فقم بمراجعة الطبيب.<br />كيف تعطي معلق أزي- ونس للأطفال الأقل من ۳ سنوات&nbsp;<br />إذا كان طفلك عمره أقل من ۳ سنوات أو يزن حتى ۱٥ كجم، يجب عليك قياس الجرعة بأقصى<br />وضوح ممكن عن طريق سرنجة الجرعات الفموية ( ۱۰ مل) المصاحبة. السرنجة مقسمة لاجزاء كل<br />جزء منها ۰٫۲٥ مل بما يوفر ۱۰ ملجم أزيثرومايسين في كل تدريج.<br />إرشادات استخدام السرنجة<br />۱. أضف الماء المرفق مع العبوة الى المسحوق في الزجاجة (لتحضير الدواء للمرة الأولى).<br />۲. رج الزجاجة جيداً &quot;حتى تتأكد تماما&quot; من الحصول علي معلق متجانس.<br />۳. إستخدم السرنجة المرفقة و انزع الغطاء و قم بسحب كمية الدواء المطلوبة.<br />٤. قم باعطاء الدواء بلطف الى طفلك فى الفم بواسطة السرنجة.<br />٥. إغسل السرنجة و قم بتغطيتها ثم أعدها الى العبوة لاعادة استعمالها فى الجرعة التالية.</p><p>كيف تعطي معلق أزي- ونس &nbsp;للأطفال ما بين سن 13-25 عام</p><table border="1" cellspacing="1" cellpadding="1" style="width:360px"><tbody><tr><td style="width:172px">الوزن والسنالجرعة والمدة</td><td style="width:186px">الجرعة والمدة</td></tr><tr><td style="width:172px">15-25 كجم (3-7 سنوات)</td><td style="width:186px">5 مل (200 ملجم)تعطي&nbsp; كملعقة 5 مل مره واحده يومياً لمدة ثلاثة أيام&nbsp;</td></tr><tr><td style="width:172px">26-35 كجم (8-11 سنوات)</td><td style="width:186px">7.5 مل (300 ملجم)تعطي&nbsp; كملعقة 7.5 مل مره واحده يومياً لمدة ثلاثة أيام</td></tr><tr><td style="width:172px">36-45&nbsp;كجم (12-14 سنوات)</td><td style="width:186px">10 مل (400 ملجم)تعطي&nbsp; كملعقة 10مل مره واحده يومياً لمدة ثلاثة ايام</td></tr></tbody></table><p>&nbsp;</p><p>تحذير: إذا أعطيت هذا الدواء لطفلك تأكد من أنه مستنداً في وضع رأسي حتى لا يتعرض للاختناق.<br />كمية أكثر مما ينبغي &trade; إذا تناولت أو تناول طفلك أزي- ونس<br />فمن الوارد أن تشعروا بالتعب. أخبر طبيبك أو &trade; إذا تناولت أو تناول طفلك كمية كبيرة من أزي- ونس<br />اتصل بقسم الحوادث في أقرب مستشفى على الفور واصطحب معك أي دواء متبقي.<br />إذا نسيت أن تتناول أو تعطي لطفلك أزي- ونس<br />في موعدها فقم بتناولها فور أن تتذكر وقم بتناول الجرعة التالية</p><p>لها في موعدها الصحيح.</p><p>إذا نسيت تناول جرعة أزي- ونس<br />لا تقم بتناول ضعف الجرعة لتعويض جرعة فائتة.<br />&nbsp;إذا توقفت عن تناول أزي- ونس<br />بشكل مبكر جدا فمن الوارد أن تعود العدوى من جديد إذا توقفت أو توقف طفلك عن تناول أزي- ونس&nbsp;يجب عليك تناول أزي- ونس<br />خلال الوقت الكامل المحدد للدواء حتى لو شعرت بالتحسن قبل .<br />انقضاء هذا الوقت.<br />إذا كان لديك المزيد من الاستفسارات حول كيفية استخدام الدواء، استشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع كل الأدوية، يمكن ل أزي- ونس أن يتسبب في تأثيرات جانبية ولكنها لا تصيب كل<br />الأشخاص. أخبر طبيبك على الفور إذا لاحظت ظهور أي من الأعراض التالية عند استخدام&nbsp;أزي- ونس<br />حيث أنه من الممكن أن تكون الأعراض حادة.&nbsp;<br />&bull; صفير مفاجئ، صعوبة في التنفس، انتفاخ جفون العين أو الوجه او الشفاة، طفح جلدي أو حكة<br />(وبخاصة التي تصيب كامل الجسم).<br />أو بعد&nbsp; &bull; إسهال حاد أو مستمر من الممكن أن يحتوى على مخاط أو دم أثناء استخدام أزي- ونس<br />استخدامه حيث أن هذه الأعراض قد تكون علامة على التهاب خطير في الأمعاء.<br />&bull; طفح جلدي حاد يسبب احمرار وتقشر.<br />&bull; سرعة أو عدم انتظام في ضربات القلب. &bull; انخفاض ضغط الدم.<br />&bull; ردود فعل جلدية خطيرة:<br />((SJS) - تقرحات في الجلد والفم والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون<br />((TEN ) - تقرحات في الجلد ، رد فعل الجلد الشديد (نخر البشرة السمية<br />- طفح جلدي مصحوب بأعراض أخرى مثل الحمى وتورم الغدد وزيادة في عدد الحمضات (نوع من<br />خلايا الدم البيضاء). يظهر الطفح الجلدي كمطبات حمراء صغيرة وحكة (التفاعلات الدوائية مع فرط<br />((DRESS) الحمضات والأعراض الجهازية<br />- طفح جلدي يتميز بظهور سريع لمناطق من البشرة الحمراء مرصعة ببثرات صغيرة (بثور صغيرة<br />.((AGEP) مملوءة بسائل أبيض / أصفر) (طفح بِثار حاد عام<br />توقف عن تناول أزيثروميسين إذا كنت تعاني من هذه الأعراض الجلدية واتصل بطبيبك أو اطلب<br />الحصول على الرعاية الطبية فوراً.<br />موجودة في القائمة أدناه. قد تختفي هذه&nbsp; الآثار الجانبية الاكثر شيوعا عند استخدام أزي- ونس<br />الأعراض خلال فترة العلاج حيث يتأقلم الجسم مع الدواء. أخبر طبيبك إذا بدأت تشعر بالضيق بسبب<br />هذه الأعراض.<br />الآثار الجانبية الشائعة جدا (تحدث في حالة على الأقل من إجمالي ۱۰ أشخاص يتعاطون الدواء):<br />تقلصات معوية، شعور بالغثيان، إسهال، ريح<br />الآثار الجانبية الشائعة (تحدث في أقل من ۱ من ۱۰ أشخاص يتعاطون الدواء):<br />الدوخة، الصداع، التنميل أو الشعور بالوخز، القئ، عسر الهضم، فقدان الشهية واضطراب في حاسة<br />التذوق، اضطراب في الرؤية، صمم، طفح جلدي او حكة، ألم في المفاصل، انخفاض في عدد الخلايا<br />وهي نوع من (eosinophils) اللمفاوية (نوع من أنواع خلايا الدم البيضاء)، زيادة عدد الحمضات<br />أنواع خلايا الدم البيضاء، انخفاض البيكربونات في الدم، التعب والوهن.<br />الآثار الجانبية غير الشائعة (تحدث في أقل من ۱ من ۱۰۰ أشخاص يتعاطون الدواء):<br />عدوى الخميرة في الفم أو المهبل (القلاع)، انخفاض عدد نوع من أنواع خلايا الدم البيضاء يسمى<br />(ليكوسايت)، انخفاض عدد خلايا العدلات (نوع من أنواع خلايا الدم البيضاء)، تفاعل تحسسي متنوع<br />الحدة، تبثر الجلد، الفم، العين، الأعضاء التناسلية، ازدياد حساسية الجلد لضوء الشمس بشكل غير<br />طبيعي، الاحساس بالعصبية والتوتر، انخفاض في حاسة اللمس أو الإحساس، النعاس أو عدم القدرة<br />على النوم (الأرق)، ضعف السمع أو طنين في الأذن، خفقان القلب، ألم في الصدر، إمساك، ألم في<br />المعدة مصحوب بحمى وإسهال، الالتهاب الكبدي، تغير في إنزيمات الكبد، فقدان عام للقوة، التورم،<br />الشعور بعدم الارتياح بشكل عام و نتائج فحوصات معملية غير طبيعية ( مثل فحوصات الدم والكبد).<br />الآثار الجانبية النادرة (تحدث في أقل من ۱ من ۱۰۰۰ أشخاص يتعاطون الدواء):<br />التهيج، الدوار و تغير في وظائف الكبد.<br />آثار جانبية أخرى بمعدل تكرار غير معروف (لا يمكن توقعها من البيانات المتاحة)<br />تشنجات أو إغماء، العدوانية أو القلق، فرط الحركة، ضعف العضلات الموضعي، فقدان أو تغير في<br />حاسة الشم و فقدان حاسة التذوق، تغير لون اللسان، التهاب البنكرياس، التهاب الكلى أو الفشل الكلوي،<br />اصفرار الجلد أو العين (الصفراء) أو فشل كبدي (نادرا ما يكون مهددا للحياة)، الكدمات أو طول<br />النزف بعد الإصابات، مخطط كهربية قلب (رسم قلب) غير طبيعي و انخفاض عدد خلايا الدم الحمراء<br />بما يؤدي إلى<br />شحوب الجلد، الوهن و ضيق التنفس<br />إذا وصلت أي من هذه الآثار الجانبية لدرجة الخطورة أو لاحظت ظهور آثار جانبية أخرى لم تذكر<br />في هذه النشرة، يرجى استشارة الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول ومرأى الأطفال.<br />يحفظ المسحوق في درجة حرارة لا تزيد عن ۳۰ درجة مئوية، بعد الإذابة يحفظ المعلق في درجة<br />حرارة لا تزيد عن ۳۰ درجة مئوية.<br />تخلص من أي محتوى غير مستخدم بعد ٥ أيام من التحضير.<br />لا تتناول أو تعطي هذا الدواء لغيرك بعد انتهاء تاريخ الصلاحية المدون على الزجاجة.<br />لا ينبغي التخلص من الأدوية عبر بالوعات الصرف أو ضمن مخلفات المنزل. اسأل الصيدلي الخاص<br />بك عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي أزيثرومايسين ( ۲۰۰ ملجم في كل ٥ مل)<br />المكونات الأخرى هي: نكهة الموز، غرواني ثاني أكسيد السيليكون، نكهة فانتازي برماسيل ، نكهة<br />فريش كو فورت بيرماسيل، هيدروكسي بروبايل سيليلوز، سكروز، فوسفات ثلاثي الصوديوم أحادي<br />الماء، صمغ زانثان و ماء منقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">معلق أزي- ونس<br />مسحوق أبيض إلى مائل للأبيض بنكهة الموز المميزة، خالي من أي كتل أو ملوثات، معبئة في زجاجة<br />٦۰ مل مع غطاء مضاد للأطفال. لعمل محلول معلق يعطي من خلال الفم ۲۰۰ ملجم/ ٥مل.<br />معلق أزي- ونس متوفر في ثلاثة عبوات تحتوى على سرنجة للجرعات الفموية و:<br />مسحوق لعمل 15 مل ( 600 ملجم) ، مسحوق لعمل 22.5 مل ( 900 ملجم) و مسحوق لعمل 30 مل<br />1200 ملجم). )<br />قد لا تكون كل أحجام العبوات مطروحة بالأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدوية المحدودة، جدة، المملكة العربية السعودية<br />- الهاتف: 608111-12-966+ فاكس :&nbsp;608222-12-966+<br />الموقع الإلكتروني:&nbsp;www.jamjoompharma.com&nbsp;<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ و السلامة الدوائية<br />- فاكس: 7662-205-11-966+&nbsp;<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.<br />هاتف: 22228302-11-966+ تحويلة: 2317-2356--2340<br />الهاتف المجاني19999<br />بريد إلكتروني:&nbsp;npc.drug@sfda.gov.sa<br />الموقع الالكتروني:&nbsp;www.sfda.gov.sa/npc<br />&bull; دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azithromycin 200 mg/ 5 ml Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azithromycin Dihydrate 41.92 (Equivalent to Azithromycin base 40 mg)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for oral suspension.
White to off white granular powder with characteristic banana flavor, free from lumps and visible
contamination, filled in 60 mL glass bottles with child resistant cap.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin powder for oral suspension is indicated for the treatment of the following<br />infections, when caused by microorganisms sensitive to azithromycin (see section 4.4 and 5.1):<br />&minus; acute bacterial sinusitis (adequately diagnosed)<br />&minus; acute bacterial otitis media (adequately diagnosed)<br />&minus; pharyngitis, tonsillitis<br />&minus; acute exacerbation of chronic bronchitis (adequately diagnosed)<br />&minus; mild to moderately severe community acquired pneumonia<br />- skin and soft tissue infections<br />- uncomplicated Chlamydia trachomatis urethritis and cervicitis<br />Considerations should be given to official guidance on the appropriate use of antibacterial<br />agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azi-Once should be given as a single daily dose. Azi-Once Suspension can be taken with or without food. Children over 45 kg body weight and adults, including elderly patients: The total dose of azithromycin is 1500 mg which should be given over three days (500 mg once daily). In uncomplicated genital infections due to Chlamydia trachomatis, the dose is 1000 mg as a single oral dose. For susceptible Neisseria gonorrhoeae the recommended dose is 1000 mg or 2000 mg of azithromycin in combination with 250 mg or 500 mg ceftriaxone according to local clinical treatment guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult local treatment guidelines.</p><p>Paediatric population: In children under 45 kg body weight: Azi-Once Suspension should be used for children under 45 kg. There is no information on children less than 6 months of age. The dose in children is 10 mg/kg as a single daily dose for 3 days: Up to 15 kg (less than 3 years): Measure the dose as closely as possible using the 10 ml oral dosing syringe provided. The syringe is graduated in 0.25 ml divisions, providing 10 mg of azithromycin in every graduation. For children weighing more than 15 kg, Azi-Once Suspension should be administered using the spoon provided according to the following guidance: 15-25 kg (3-7 years): 5 ml (200 mg) given as 1 x 5 ml spoonful, once daily for 3 days. 26-35 kg (8-11 years): 7.5 ml (300 mg) given as 1 x 7.5 ml spoonful, once daily for 3 days. 36-45 kg (12-14 years): 10 ml (400 mg) given as 1 x 10 ml spoonful, once daily for 3 days. Over 45 kg: Dose as per adults. See section 6.5 for appropriate pack size to use depending on age/body weight of child. The specially supplied measure should be used to administer Azi-Once suspension to children. Renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80 ml/min). Caution should be exercised when azithromycin is administered to patients with severe renal impairment (GFR &lt; 10 ml/min) (see section 4.4 and section 5.2). Hepatic impairment: Since azithromycin is metabolised in the liver and excreted in the bile, the drug should not be given to patients suffering from severe liver disease. No studies have been conducted regarding treatment of such patients with azithromycin (see section 4.4). Method of administration: Azi-Once Suspension is for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azi-Once is contra-indicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients (listed in section 6.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity As with erythromycin and other macrolides, serious allergic reactions including angioneurotic oedema and anaphylaxis (rarely fatal), Acute Generalized Exanthematous Pustulosis (AGEP) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.</p><p>Hepatotoxicity Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see section 4.8). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests / investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged. Ergot derivatives In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administrated. Prolongation of the QT interval Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarisation (see section 4.8); therefore caution is required when treating patients: &bull; With congenital or documented QT prolongation &bull; Currently receiving treatment with other active substance known to prolong QT interval such as antiarrhythmics of Classes Ia and III, cisapride and terfenadine &bull; With electrolyte disturbance, particularly in case of hypokalaemia and hypomagnesemia &bull; With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency. Superinfection As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms including fungi is recommended. Clostridium difficile associated diarrhoea Clostridium difficile associated diarrhoea (CDAD) has been reported with the use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal colitis. Strains of C. difficile producing hypertoxin A and B contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. Therefore, CDAD must be considered in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the&nbsp;administration of antibacterial agents. Discontinuation of therapy with azithromycin and the administration of specific treatment for C. difficile should be considered. Streptococcal infections Penicillin is usually the first choice for treatment of pharyngitis/tonsillitis due to Streptococcus pyogenes and also for prophylaxis of acute rheumatic fever. Azithromycin is in general effective against streptococcus in the oropharynx, but no data are available that demonstrate the efficacy of azithromycin in preventing acute rheumatic fever. Renal impairment In patients with severe renal impairment (GFR &lt;10 ml/min) a 33% increase in systemic exposure to azithromycin was observed (see section 5.2). Myasthenia gravis Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see section 4.8). Diabetes Caution in diabetic patients: 5 ml of reconstituted suspension contains 3.87 g of sucrose. Excipients information Azi-Once suspension contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Azi-Once suspension contains less than 1 mmol sodium (23 mg) per 5 ml of reconstituted suspension, that is to say essentially &#39;sodium-free&#39;. Azi-Once Suspension is for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antacids: In a pharmacokinetic study investigating the effects of simultaneous administration of<br />antacids and azithromycin, no effect on the total bio-availability was seen, although the peak<br />serum concentrations were reduced by approximately 25%. Azithromycin must be taken at least<br />1 hour before or 2 hours after antacids.</p><p>Cetirizine: In healthy volunteers, co-administration of a 5-day regimen of azithromycin with<br />cetirizine 20 mg at steady-state resulted in no pharmacokinetic interaction and no significant<br />changes in the QT interval.</p><p>Didanosins (Dideoxyinosine): Co-administration of 1,200 mg/day azithromycin with 400 mg/day<br />didanosine in 6 HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of<br />didanosine as compared with placebo.</p><p>Digoxin: Some of the macrolide antibiotics have been reported to impair the microbial metabolism<br />of digoxin in the gut in some patients. In patients receiving concomitant azithromycin, a related<br />azalide antibiotic, and digoxin the possibility of raised digoxin levels should be borne in mind.</p><p>Zidovudine: Single 1,000 mg doses and multiple 1,200 mg or 600 mg doses of azithromycin had<br />little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide<br />metabolite. However, administration of azithromycin increased the concentrations of phosphorylated<br />zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical<br />significance of this finding is unclear, but it may be of benefit to patients.</p><p>Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not<br />believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other<br />macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex<br />does not occur with azithromycin.</p><p>Ergotamine derivatives: Due to the theoretical possibility of ergotism, the concurrent use of<br />azithromycin with ergot derivatives is not recommended (see section 4.4).<br />Pharmacokinetic studies have been conducted between azithromycin and the following drugs known<br />to undergo significant cytochrome P450 mediated metabolism.</p><p>Astemizole, alfentanil</p><p>There are no known data on interactions with astemizole or alfentanil. Caution is advised in the coadministration<br />of these medicines with Azithromycin because of the known enhancing effect of these medicines when used concurrently with the macrolid antibiotic erythromycin.</p><p>Atorvastatin: Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did<br />not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition<br />assay).</p><p>Carbamazepine: In a pharmacokinetic interaction study in healthy volunteers, no significant effect<br />was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving<br />concomitant azithromycin.</p><p>Cisapride</p><p>Cisapride is metabolized in the liver by the enzyme CYP 3A4. Because macrolides inhibit this<br />enzyme, concomitant administration of cisapride may cause the increase of QT interval<br />prolongation, ventricular arrhythmias and torsades de pointes.</p><p>Cimetidine: In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given<br />2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin<br />pharmacokinetics was seen.</p><p>Coumarin-Type Oral Anticoagulants: In a pharmacokinetic interaction study, azithromycin did not<br />alter the anticoagulant effect of a single 15-mg dose of warfarin administered to healthy volunteers.<br />There have been reports received in the post-marketing period of potentiated anticoagulation<br />subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a<br />causal relationship has not been established, consideration should be given to the frequency of<br />monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral<br />anticoagulants.</p><p>Ciclosporin: In a pharmacokinetic study with healthy volunteers that were administered a 500<br />mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose<br />of cyclosporin, the resulting cyclosporin Cmax and AUC0-5 were found to be significantly elevated.<br />Consequently, caution should be exercised before considering concurrent administration of these<br />drugs. If co-administration of these drugs is necessary, cyclosporin levels should be monitored and<br />the dose adjusted accordingly.</p><p>Efavirenz: Co-administration of a 600 mg single dose of azithromycin and 400 mg efavirenz daily<br />for 7 days did not result in any clinically significant pharmacokinetic interactions.</p><p>Fluconazole: Co-administration of a single dose of 1,200 mg azithromycin did not alter the<br />pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of<br />azithromycin were unchanged by the co-administration of fluconazole, however, a clinically<br />insignificant decrease in Cmax (18%) of azithromycin was observed.</p><p>Indinavir: Co-administration of a single dose of 1,200 mg azithromycin had no statistically<br />significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for<br />5 days.</p><p>Methylprednisolone: In a pharmacokinetic interaction study in healthy volunteers, azithromycin had<br />no significant effect on the pharmacokinetics of methylprednisolone.</p><p>Midazolam: In healthy volunteers, co-administration of azithromycin 500 mg/day for 3 days did not<br />cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single 15<br />mg dose of midazolam.</p><p>Nelfinavir: Co-administration of azithromycin (1,200 mg) and nelfinavir at steady state (750 mg<br />three times daily) resulted in increased azithromycin concentrations. No clinically significant<br />adverse effects were observed and no dose adjustment is required.</p><p>Rifabutin: Co-administration of azithromycin and rifabutin did not affect the serum concentrations<br />of either drug.</p><p>Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and<br />rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to<br />combination with azithromycin has not been established (see section 4.8).</p><p>Sildenafil: In normal healthy male volunteers, there was no evidence of an effect of azithromycin<br />(500 mg daily for 3 days) on the AUC and Cmax of sildenafil or its major circulating metabolite.<br />Terfenadine: Pharmacokinetic studies have reported no evidence of an interaction between<br />azithromycin and terfenadine. There have been rare cases reported where the possibility of such an<br />interaction could not be entirely excluded; however there was no specific evidence that such an<br />interaction had occurred.</p><p>Theophylline: There is no evidence of a clinically significant pharmacokinetic interaction when<br />azithromycin and theophylline are co-administered to healthy volunteers. As interactions of other<br />macrolides with theophylline have been reported, alertness to signs that indicate a rise in<br />theophylline levels is advised.</p><p>Triazolam: In 14 healthy volunteers, co-administration of azithromycin 500 mg on Day 1 and 250<br />mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the<br />pharmacokinetic variables for triazolam compared to triazolam and placebo.</p><p>Trimethoprim/sulfamethoxazole: Co-administration of trimethoprim/sulfamethoxazole DS (160<br />mg/800 mg) for 7 days with azithromycin 1,200 mg on Day 7 had no significant effect on peak<br />concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole.<br />Azithromycin serum concentrations were similar to those seen in other studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Animal reproduction studies have been performed at doses up to moderately maternally toxic dose concentrations. In these studies, no evidence of harm to the foetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed. Breast-feeding Limited information available from published literature indicates that azithromycin is present in human milk at an estimated highest median daily dose of 0.1 to 0.7 mg/kg/day. No serious adverse effects of azithromycin on the breast-fed infants were observed. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from azithromycin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence to suggest that Azi-Once may have an effect on a patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below lists the adverse reactions identified through clinical trial experience and postmarketing surveillance by system organ class and frequency.</p><p>The frequency grouping is defined using the following convention: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); and not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance:</strong></p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Very Common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td colspan="" rowspan=""><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td colspan="" rowspan=""><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1000 to &lt; 1/100)</strong></p></td><td colspan="" rowspan=""><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to &lt;1/1,000)</strong></p><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Frequency Not Known</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Infections and Infestations</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Candidiasis</p><p>Vaginal infection</p><p>Pneumonia</p><p>Fungal infection</p><p>Bacterial infection</p><p>Pharyngitis</p><p>Gastroenteritis</p><p>Respiratory disorder</p><p>Rhinitis</p><p>Oral candidiasis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Pseudomembranous colitis (see section 4.4)</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Leukopenia</p><p>Neutropenia</p><p>Eosinophilia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Thrombocytopenia</p><p>Haemolytic anaemia</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Immune System Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Angioedema</p><p>Hypersensitivity</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>severe (partly fatal) anaphylactic reaction e.g. anaphylactic shock (see section 4.4)</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Anorexia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Psychiatric Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Nervousness</p><p>Insomnia,</p></td><td colspan="" rowspan=""><p>Agitation</p></td><td colspan="" rowspan=""><p>Aggression</p><p>Anxiety</p><p>Delirium</p><p>Hallucination</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Nervous System Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Headache</p></td><td colspan="" rowspan=""><p>Dizziness</p><p>Somnolence</p><p>Dysgeusia</p><p>Paraesthesia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Syncope, convulsion</p><p>Hypoestheia</p><p>Psychomotor hyperactivity</p><p>Anosmia</p><p>Ageusia</p><p>Parosmia</p><p>Myasthenia gravis (see Section 4.4)</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Eye Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Visual impairment, blurred vision</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Ear and Labyrinth Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Ear disorder</p><p>Vertigo</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Hearing impairment including deafness and/or tinnitus</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Cardiac Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Palpitations</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Torsades de pointes (see section 4.4)</p><p>Arrhythmia (see section 4.4) including ventricular tachycardia</p><p>Electrocardiogram QT prolonged (see section 4.4)</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Vascular Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Hot flush</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Hypotension</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Dyspnoea,</p><p>Epistaxis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Gastrointestinal Disorders</strong></p></td><td colspan="" rowspan=""><p>Diarrhea</p></td><td colspan="" rowspan=""><p>Vomiting</p><p>Abdominal pain</p><p>Nausea</p></td><td colspan="" rowspan=""><p>Constipation</p><p>Flatulence</p><p>Dyspepsia,</p><p>Gastritis dysphagia</p><p>Abdominal distension</p><p>Dry mouth</p><p>Eructation</p><p>Mouth ulceration</p><p>Salivary hypersecretion</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Pancreatitis</p><p>Tongue discolouration</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Hepatobiliary Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Hepatic function abnormal</p><p>Jaundice cholestatic</p></td><td colspan="" rowspan=""><p>Hepatic failure (which has rarely resulted in death) (see section 4.4)</p><p>Hepatitis fulminant</p><p>Hepatic necrosis</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rash</p><p>Pruritus</p><p>Urticaria,</p><p>Dermatitis</p><p>Dry skin</p><p>Hyperhidrosis</p></td><td colspan="" rowspan=""><p>Photosensitivity reaction</p><p>Acute generalised exanthematous pustulosis (AGEP) DRESS (drug reaction with eosinophilia and systemic symptoms)</p></td><td colspan="" rowspan=""><p>Stevens-Johnson syndrome</p><p>Toxic epidermal necrolysis</p><p>Erythema multiforme</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Osteoarthritis,</p><p>Myalgia</p><p>Back pain</p><p>Neck pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Arthralgia</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Renal and Urinary Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Dysuria</p><p>Renal pain</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Renal failure acute</p><p>Nephritis interstitial</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Reproductive system and breast disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Metrorrhagia,</p><p>Testicular disorder</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Injection site pain</p><p>* Injection site inflammation</p></td><td colspan="" rowspan=""><p>Oedema</p><p>Asthenia</p><p>Malaise</p><p>Fatigue</p><p>Face edema</p><p>Chest pain</p><p>Pyrexia</p><p>Pain</p><p>Peripheral edema</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Investigations</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Lymphocyte count decreased</p><p>Eosinophil count increased</p><p>Blood bicarbonate decreased</p><p>Basophils increased</p><p>Monocytes increased</p><p>Neutrophils increased</p></td><td colspan="" rowspan=""><p>Aspartate aminotransferase increased</p><p>Alanine aminotransferase increased</p><p>Blood bilirubin increased</p><p>Blood urea increased</p><p>Blood creatinine increased</p><p>Blood potassium abnormal</p><p>Blood alkaline phosphatase increased</p><p>Chloride increased</p><p>Glucose increased platelets increased</p><p>Hematocrit decreased</p><p>Bicarbonate increased abnormal sodium</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Injury and poisoning</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Post procedural complication</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr></tbody></table><p>Adverse reactions possibly or probably related to Mycobacterium Avium Complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions&nbsp;<u>differ</u>&nbsp;from those reported with immediate release or the prolonged release formulations, either in kind or in frequency:</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Very Common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td colspan="" rowspan=""><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td colspan="" rowspan=""><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to &lt;1/1,000)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Anorexia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Nervous System Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Dizziness</p><p>Headache</p><p>Paraesthesia</p><p>Dysgeusia</p></td><td colspan="" rowspan=""><p>Hypoesthesia</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Eye Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Visual impairment</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Ear and Labyrinth Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Deafness</p></td><td colspan="" rowspan=""><p>Hearing impaired</p><p>Tinnitus</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Cardiac Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Palpitations</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Gastrointestinal Disorders</strong></p></td><td colspan="" rowspan=""><p>Diarrhea</p><p>Abdominal pain</p><p>Nausea</p><p>Flatulence</p><p>Abdominal discomfort</p><p>Loose stools</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Hepatobiliary Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Hepatitis</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Rash</p><p>Pruritus</p></td><td colspan="" rowspan=""><p>Stevens-Johnson syndrome</p><p>Photosensitivity reaction</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Arthralgia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Fatigue</p></td><td colspan="" rowspan=""><p>Asthenia</p><p>Malaise</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>To report any side effect(s): &bull; Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2340. Toll free phone: 19999 E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General properties Pharmacotherapeutic group: Antibacterials for systemic use. ATC code: J01FA10 Mode of action: Azi-Once is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation. Mechanism of resistance: Resistance to azithromycin may be inherent or acquired. There are three main mechanisms of resistance in bacteria: target site alteration, alteration in antibiotic transport and modification of the antibiotic. Azithromycin demonstrates cross resistance with erythromycin resistant gram positive isolates. A decrease in macrolide susceptibility over time has been noted particularly in Streptococcus pneumoniae and Staphylococcus aureus. Similarly, decreased susceptibility has been observed among Streptococcus viridans and Streptococcus agalactiae (Group B) streptococcus against other macrolides and lincosamides. Breakpoints Azithromycin susceptibility breakpoints for typical bacterial pathogens published by EUCAST are:</p><p><strong>Breakpoints</strong></p><p>EUCAST (European Committee on Antimicrobial Susceptibility Testing)</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>Pathogens</strong></p></td><td colspan="" rowspan=""><p><strong>susceptible (mg/l)</strong></p></td><td colspan="" rowspan=""><p><strong>resistant (mg/l)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Staphylococcus</em>&nbsp;spp.<sup>&nbsp;1</sup></p></td><td colspan="" rowspan=""><p>&le; 1</p></td><td colspan="" rowspan=""><p>&gt; 2</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus</em>&nbsp;spp. (Group A, B, C, G)<sup>1</sup></p></td><td colspan="" rowspan=""><p>&le; 0.25</p></td><td colspan="" rowspan=""><p>&gt; 0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae</em><sup>1</sup></p></td><td colspan="" rowspan=""><p>&le; 0.25</p></td><td colspan="" rowspan=""><p>&gt; 0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Haemophilus influenzae</em></p></td><td colspan="" rowspan=""><p>Note<sup>2</sup></p></td><td colspan="" rowspan=""><p>Note<sup>2</sup></p></td></tr><tr><td colspan="" rowspan=""><p><em>Moraxella catarrhalis</em><sup>1</sup></p></td><td colspan="" rowspan=""><p>&le; 0.25</p></td><td colspan="" rowspan=""><p>&gt; 0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Neisseria gonorrhoeae</em></p></td><td colspan="" rowspan=""><p>Note<sup>3</sup></p></td><td colspan="" rowspan=""><p>Note<sup>3</sup></p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Erythromycin can be used to determine susceptibility to azithromycin.</p><p><sup>2</sup>&nbsp;Clinical evidence for the efficacy of macrolides in&nbsp;<em>H. influenzae</em>&nbsp;respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFF for azithromycin is 4 mg/L.</p><p><sup>3</sup>&nbsp;Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.</p><p><strong>Susceptibility</strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Pathogens for which resistance may be a problem: prevalence of resistance is equal to or greater than 10% in at least one country in the European Union.</p><p>Table of susceptibility</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Aerobic Gram-negative microorganisms</p></td></tr><tr><td colspan="" rowspan=""><p><em>Haemophilus influenzae*</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Moraxella catarrhalis*</em></p></td></tr><tr><td colspan="" rowspan=""><p>Other microorganisms</p></td></tr><tr><td colspan="" rowspan=""><p><em>Chlamydophila pneumoniae</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Chlamydia trachomatis</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Legionella pneumophila</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Mycobacterium avium</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Mycoplasma pneumonia*</em></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Aerobic Gram-positive microorganisms</p></td></tr><tr><td colspan="" rowspan=""><p><em>Staphylococcus aureus</em>*</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae*</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pyogenes*</em></p></td></tr><tr><td colspan="" rowspan=""><p>Other microorganisms</p></td></tr><tr><td colspan="" rowspan=""><p><em>Ureaplasma urealyticum</em></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Aerobic Gram-positive microorganisms</p><p><em>Staphylococcus aureus &ndash;&nbsp;</em>methicillin resistant and erythromycin resistant strains</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae &ndash;&nbsp;</em>penicillin resistant strains</p></td></tr><tr><td colspan="" rowspan=""><p>Aerobic Gram-negative microorganisms</p><p><em>Escherichia coli</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Klebsiella&nbsp;</em>spp.</p><p>Anaerobic Gram-negative microorganisms</p><p><em>Bacteroides fragilis-group</em></p></td></tr></tbody></table><p>* Clinical effectiveness is demonstrated by sensitive isolated organisms for approved clinical indications.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption Bioavailability after oral administration is approximately 37%. Peak plasma concentrations are attained 2 to 3 hours after taking the medicinal product. Distribution Orally administered azithromycin is widely distributed throughout the body. In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues. Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5 microgram/ml up to 52% at 0.05 microgram azithromycin/ml serum. The mean volume of distribution at steady state (VVss) has been calculated to be 31.1 l/kg. Elimination The terminal plasma elimination half-life closely reflects the elimination half-life from tissues of 2 to 4 days. Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in urine within the following three days. Particularly high concentrations of unchanged azithromycin have been found in human bile. Also in bile, ten metabolites were detected, which were formed through N- and O- demethylation, hydroxylation of desosamine and aglycone rings and cleavage of cladinose conjugate. Comparison of the results of liquid&nbsp;chromatography and microbiological analyses has shown that the metabolites of azithromycin are not microbiologically active. In animal tests, high concentrations of azithromycin have been found in phagocytes. It has also been established that during active phagocytosis higher concentrations of azithromycin are released from inactive phagocytes. In animal models this results in high concentrations of azithromycin being delivered to the site of infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g. eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs. The effect has been shown to be reversible after cessation of azithromycin treatment. The significance of the finding for animals and humans is unknown. Carcinogenic potential: Long-term studies in animals have not been performed to evaluate carcinogenic potential as the drug is indicated for short-term treatment only and there were no signs indicative of carcinogenic activity. Mutagenic potential: There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test models. Reproductive toxicity: In animal studies for embryotoxic effects of the substance, no teratogenic effect was observed in mice and rats. In rats, azithromycin doses of 100 and 200 mg/kg bodyweight/day led to mild retardation of foetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardation following treatment with 50 mg/kg/day azithromycin and above was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xanthan Gum<br />Trisodium phosphate monohydrate<br />Hydroxy propyl cellulose<br />Banana Flavour<br />Fantasy flavour permaseal<br />Fresh co forte flavour permaseal<br />Colloidal silicon dioxide<br />Sucrose<br />Purified water for reconstitution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azi-Once Powder for Oral Suspension: 3 years. Once reconstituted with water, 
Azi-Once Suspension has a shelf-life of 5 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store dry powder at temperature not exceeding 30 &ordm;C, and after reconstitution store at temperature not exceeding 30 &ordm;C. Discard any unused portion after 5 days of reconstitution</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azi-Once&trade; Suspension available in three packages containing an oral dosing syringe and : powder to make 15ml (600 mg), powder to make 22.5 ml (900 mg) and powder to make 30 ml (1200 mg). Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company, 
Plot No. ME 1:3, 
Phase V, 
Industrial City, 
Jeddah
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mar- 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>